Introduction: WOC2020 Virtual®
Symposia highlights: Novel therapies and retinal fluid management
Symposia highlights: Home monitoring and novel delivery systems
Congress abstracts on novel treatments for nAMD
Video Player Controls:
Prof. Frank G Holz, Professor and Chair of the Department of Ophthalmology at the University of Bonn, Germany, provides his expert insights into the key data from WOC2020 Virtual on the management of nAMD in a post-COVID-19 era.
Prof. Pravin Dugel, a leading retinal specialist from Phoenix, AZ, USA, provides his expert insights into the key data from WOC2020 Virtual on the management of nAMD in a post-COVID-19 era.
Dr Kelvin Teo from the Medical Retina Department, Singapore National Eye Centre, Singapore, provides his expert insights into the key data from WOC2020 Virtual on the management of nAMD in a post-COVID-19 era.
Please Select A Video:
Overview & Learning Objectives
In this activity, internationally recognized experts in ophthalmology discuss the latest data on the clinical management of nAMD, including the importance of regular monitoring, application of optimal dosing regimens for individual patients and role of novel drug delivery systems and agents.
This activity has been jointly provided by Oakstone and touchIME. Oakstone Publishing is accredited by the ACCME to provide continuing medical education to physicians.
This activity is designed to meet the educational needs of ophthalmologists and retinal disease specialists worldwide.
Oakstone Publishing has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing’s planners, content reviewers, and editorial staff disclose no relevant commercial interests.
Prof. Pravin Dugal Discloses: Advisory board member: Acucela, Aerpio, Alcon Pharmaceutical, Alcon Surgical (RACII), Alimera Sciences, Abbott Medical Optics Incs, Annidis, ArticDX, ASRS Board, Avalanche, Bausch, Beyeonics, CDR-Life Inc., Clearside Biomedical, Digisight, DOSE Medical, Euretina Board, Gemini Pharmaceutical, Genentech, Graybug Vision, Lutronic, LUX BioScience, MacuSight, NeoVista, Neurotech, Novartis, Oculis, Omeros, Opthea, Ophthotech, Orbis International, Oxurion, Regenxbio, Reneuron, Retina World Congress, Roche, Santen, Inc, Shire Human Genetics, Stealth Biotherapeutics, Thrombogenics and TrueVision; Consultant for, Acucela, Aerie Pharmaceutical, Aerpio, Alcon Pharmaceutical, Alcon Surgical, Allergan, Alimera Sciences, Amgen, Annidis, ArticDX, Arctic Vision, AsclepiX Therapeutics Inc., Bausch & Lomb Pharma, BeyeOnics, BioBridge/Retinagenix, Boehringer Ingelheim, Chengdu Kanghong Biotechnology, Clearside Biomedical, Daiichi Sankyo, DigiSight, DOSE Medical, FoxKiser, Gemini Pharmaceutical, Genentech, Glaukos, Graybug Vision, Kodiak Sciences, Irenix, jCyte, Ionis, Lutronic, LUX BioScience, MacuSight, Merck, Nan Fung Group, NeoVista, Neurotech, Novartis, Oculis SA, Omeros, Opthea, Ophthotech, Optovue, ORA, PanOptica, Pentavision, Pieris Pharmaceutical, pSiveda/Eyepoint, RegenexBio, Reneuron. Roche, Santen, Inc., SciFluor Life Sciences, Shire Human Genetics, Spark Therapeutics, Stealth Biotherapeutics, Thrombogenics, TopCon and Zeiss Group; Minor stockholder with: Aerpio, Allegro, ArctixDx, Arctic Vision, Clearside Biomedical, Digisight/Verana, FoxKiser, Graybug, Irenix, Nan Fung Group, Oculis, Ophthotech, PanOptica, SciFluor and TrueVision. Employee and shareholder: IVERIC Bio.
Walter Murray Yarbrough, MD, FACP, has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Kathy Day has no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing and touchIME. Oakstone Publishing is accredited by the ACCME to provide continuing medical education for physicians.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu)
Oakstone Publishing designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to receive credit for this activity, participants must review and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
Date of original release: 22 July 2020. Date credits expire: 22 July 2021.
After watching this touchCONGRESS, you should be able to:
- Evaluate strategies for the management of retinal fluid in nAMD
- Interpret results from clinical trials and real-world experience to inform on optimal dosing of anti-VEGF in nAMD
- Recall factors that contribute to optimization of clinical management and reduction in treatment burden for patients with nAMD